NDAINTRAVESICALSYSTEMPriority Review
Approved
Sep 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
Priority Review
INLEXZO (gemcitabine intravesical) by Johnson & Johnson is nucleic acid synthesis inhibitors [moa]. Approved for nucleoside metabolic inhibitor [epc]. First approved in 2025.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INLEXZO is a gemcitabine intravesical system approved by the FDA in September 2025 for direct bladder instillation therapy. It works as a nucleoside metabolic inhibitor that disrupts nucleic acid synthesis in target cells. This small-molecule formulation represents a novel intravesical delivery approach for bladder-related indications.
Growth8.3 years to LOE
Early-stage launch product with minimal established market presence creates opportunity for growth-phase positioning and team expansion across commercial and medical functions.
Mechanism of Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Class:
Nucleoside Metabolic Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer
Started Dec 2003
90 enrolled
Superficial Bladder Cancer
Career Relevance
Working on INLEXZO positions professionals in a high-visibility J&J launch with emerging market opportunity and minimal legacy organizational structures, enabling rapid career impact and team-building authority. The early-stage lifecycle combined with zero competitive pressure creates significant scope for strategic decision-making in commercial positioning, clinical affairs, and market access roles.
Director
Worked on INLEXZO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.